TCRT | Alaunos Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.7650 - 1.8700
52 Week Range	1.6300 - 33.00
Beta	0.05
Implied Volatility	286.16%
IV Rank	54.90%
Day's Volume	9,841
Average Volume	24,790
Shares Outstanding	1,601,250
Market Cap	2,826,206
Sector	Healthcare
Industry	Biotechnology
IPO Date	2005-08-24

Valuation
Profitability
Growth
Health
P/E Ratio	-0.01
Forward P/E Ratio	N/A
EPS	-315.39
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	1
Country	USA
Website	TCRT

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.

TCRT's peers: RIGL, INKT, PIRS, MRSN, VRCA, FENC, LRMR, LIAN, ADAP, STOK, FIXX, BDTX, HARP, ACHL, CKPT, CUE, MDNA

*Chart delayed

Analyzing fundamentals for TCRT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see TCRT Fundamentals page.

Watching at TCRT technicals we can see that long-term trend is bearish, while middle-term trend is bullish, but short-term trend is bearish. More technicals details can be found on TCRT Technicals page.